Diagnosis and Management of Atrial Fibrillation
Diagnosis and Management of Atrial Fibrillation (AF), aligned with ESC / ACC-AHA principles and suitable for UGโPGโSS level preparation as well as bedside decision-making.
I. DIAGNOSIS OF ATRIAL FIBRILLATION
A. Definition
- Supraventricular tachyarrhythmia with:
- Irregularly irregular RR intervals
- Absent distinct P waves
- Fibrillatory baseline
Diagnosis requires ECG documentation โฅ30 seconds (ESC).
B. ECG Features
- No P waves
- Variable RR intervals
- Narrow QRS (unless aberrancy / pre-existing BBB)
- Fibrillatory (f) waves (best in V1)
C. Classification (ESC)
| Type | Definition |
|---|---|
| First-diagnosed | First documented AF |
| Paroxysmal | Terminates spontaneously โค7 days |
| Persistent | >7 days or needs cardioversion |
| Long-standing persistent | โฅ12 months |
| Permanent | Rhythm control abandoned |
D. Etiological Evaluation (โAF Work-upโ)
- Structural heart disease (Echo)
- Valvular disease (esp. MS โ valvular AF)
- Hypertension
- CAD / HF
- Thyroid dysfunction
- Alcohol (โholiday heartโ)
- Infection, electrolyte imbalance
E. Baseline Investigations
- 12-lead ECG
- Transthoracic echocardiography
- TSH
- Renal & liver function
- Holter / event monitor (paroxysmal AF)
- CHAโDSโ-VASc & HAS-BLED scoring
II. MANAGEMENT STRATEGIES IN ATRIAL FIBRILLATION
AF management rests on 4 pillars (โAF-CAREโ concept):
1๏ธโฃ C โ Control Stroke Risk (Anticoagulation)
A. CHAโDSโ-VASc Score
| Risk Factor | Points |
|---|---|
| CHF/LV dysfunction | 1 |
| Hypertension | 1 |
| Age โฅ75 | 2 |
| Diabetes | 1 |
| Stroke/TIA | 2 |
| Vascular disease | 1 |
| Age 65โ74 | 1 |
| Sex (female) | 1 |
Anticoagulate if:
- Men โฅ2
- Women โฅ3
B. Anticoagulation Choices
- NOACs preferred (non-valvular AF):
- Apixaban
- Rivaroxaban
- Dabigatran
- Edoxaban
- Warfarin (INR 2โ3):
- Mechanical valve
- Moderateโsevere mitral stenosis
C. Bleeding Risk
- HAS-BLED score (assess risk, not a contraindication)
2๏ธโฃ A โ Achieve Rate Control
Target Heart Rate
- Lenient: <110 bpm (most patients)
- Strict: <80 bpm (symptomatic / HF)
Drugs for Rate Control
| Clinical Scenario | Preferred Agents |
|---|---|
| No HF | ฮฒ-blocker / Diltiazem / Verapamil |
| HFrEF | ฮฒ-blocker + Digoxin |
| Acute | IV ฮฒ-blocker / Diltiazem |
| Hypotension | Digoxin / Amiodarone |
Avoid non-DHP CCBs in HFrEF
3๏ธโฃ R โ Restore & Maintain Sinus Rhythm (Rhythm Control)
Indications
- Symptomatic AF
- Young patients
- AF-induced cardiomyopathy
- HF with reduced EF
- Early AF (EAST-AFNET 4 trial)
Rhythm Control Options
A. Electrical Cardioversion
- Hemodynamic instability โ Immediate DC cardioversion
- Stable โ after anticoagulation or TEE-guided
B. Pharmacological Cardioversion
| Drug | Use |
|---|---|
| Flecainide / Propafenone | No structural heart disease |
| Amiodarone | Structural heart disease / HF |
| Ibutilide | IV (QT prolongation risk) |
C. Maintenance of Sinus Rhythm
| Heart Status | Drug |
|---|---|
| Normal heart | Flecainide / Propafenone |
| CAD | Sotalol |
| HF / LV dysfunction | Amiodarone |
| Recurrent AF | Catheter ablation |
D. Catheter Ablation
- Pulmonary vein isolation
- Indications:
- Symptomatic AF despite โฅ1 AAD
- First-line in selected paroxysmal AF
- AF with HFrEF (improves outcomes)
4๏ธโฃ E โ Evaluate & Treat Comorbidities
- Hypertension control
- Weight loss
- Treat OSA
- Diabetes management
- Alcohol reduction
- Exercise optimization
III. SPECIAL SITUATIONS
A. AF with Hemodynamic Instability
โ Immediate synchronized DC cardioversion
B. AF with WPW
- Avoid AV nodal blockers
- Use:
- Procainamide
- DC cardioversion
C. Post-operative AF
- Rate control + short-term anticoagulation
- Often self-limiting
IV. KEY EXAM PEARLS (High-Yield)
- Irregularly irregular pulse = AF until proven otherwise
- Anticoagulation is independent of rhythm control
- Rate control โ stroke prevention
- NOACs contraindicated in mechanical valves
- Early rhythm control improves outcomes (EAST-AFNET 4)
1. AFFIRM trialโs most practice-changing conclusion?
A. Rhythm control superior for mortality
B. No mortality benefit with rhythm control
C. Rhythm control prevents stroke without OAC
D. Ablation superior to drugs
AFFIRM showed no survival advantage of rhythm control and more adverse effects.
2. RACE II trial validated which heart rate strategy?
A. Lenient <110 bpm
B. Strict <80 bpm
C. Individualized only
D. <70 bpm mandatory
Lenient rate control was non-inferior to strict control.
3. EAST-AFNET 4 differed from AFFIRM primarily by:
A. Excluding anticoagulation
B. Early rhythm control within 1 year
C. Including only ablation
D. Younger population only
Early rhythm control was initiated soon after AF diagnosis.
4. EAST-AFNET 4 primary endpoint included all EXCEPT:
A. Stroke
B. CV death
C. HF hospitalization
D. AF recurrence
AF recurrence was not part of the composite primary endpoint.
5. ARISTOTLE showed apixaban reduced all EXCEPT:
A. Stroke
B. Major bleeding
C. Mortality
D. Myocardial infarction
MI reduction was not a primary finding.
6. Dabigatran dose superior to warfarin in stroke prevention (RE-LY)?
A. 75 mg BID
B. 150 mg BID
C. 110 mg OD
D. 220 mg OD
150 mg BID reduced stroke with similar major bleeding.
7. RE-LY trial design was unique because it was:
A. Open-label warfarin arm
B. Double-blind for all arms
C. Registry-based
D. Non-inferiority only
Warfarin arm was open-label.
8. ROCKET-AF population differed by:
A. Higher baseline stroke risk
B. Younger patients
C. More valvular AF
D. Less HF
ROCKET-AF enrolled high-risk patients (mean CHADSโ โ3.5).
9. ENGAGE-AF showed edoxaban was:
A. Non-inferior with less bleeding
B. Inferior to warfarin
C. Superior for mortality
D. Unsafe in renal disease
High-dose edoxaban: non-inferior efficacy, less bleeding.
10. CASTLE-AF mandated which inclusion?
A. ICD or CRT-D
B. Preserved EF
C. Post-MI AF only
D. Valvular AF
Only HFrEF patients with device monitoring were included.
11. CASTLE-AF primary benefit was reduction in:
A. Stroke only
B. Death and HF hospitalization
C. AF recurrence only
D. Bleeding
Ablation reduced mortality and HF admissions.
12. CABANA trial was neutral due to:
A. High crossover
B. Underpowered design
C. Wrong endpoints
D. Excess ablation deaths
Crossover diluted intention-to-treat results.
13. APAF-CRT showed AV node ablation + CRT improved:
A. Survival
B. Stroke only
C. Bleeding
D. AF recurrence
Mortality reduction in permanent AF with HF.
14. ANDROMEDA trial stopped early due to:
A. Excess mortality with dronedarone
B. Liver failure
C. Stroke risk
D. QT prolongation
Dronedarone harmful in severe HF.
15. PIONEER-AF PCI favored:
A. NOAC + SAPT
B. Triple therapy 12 months
C. DAPT alone
D. Warfarin monotherapy
Bleeding reduction with NOAC + single antiplatelet.
16. RE-DUAL PCI tested:
A. Dabigatran dual therapy
B. Apixaban triple therapy
C. Rivaroxaban monotherapy
D. Edoxaban + aspirin
Dabigatran + P2Y12 reduced bleeding.
17. AUGUSTUS showed lowest bleeding with:
A. Apixaban + P2Y12
B. Warfarin + aspirin
C. Triple therapy
D. DAPT alone
Avoid aspirin when possible.
18. ELIMINATE-AF evaluated:
A. Edoxaban peri-ablation
B. Dabigatran cardioversion
C. Rivaroxaban PCI
D. Apixaban stroke prevention
Edoxaban was safe vs VKA during ablation.
19. Stroke risk reduction in AF is primarily independent of:
A. Rhythm control strategy
B. CHAโDSโ-VASc score
C. Anticoagulation
D. Age
OAC required irrespective of rhythm vs rate control.
20. AF ablation improves mortality most clearly in:
A. HFrEF patients
B. Elderly asymptomatic
C. Valvular AF
D. Post-operative AF
Best evidence from CASTLE-AF.
21. A 68-year-old man with AF has HR 140/min, BP 80/50 mmHg, cold extremities. ECG shows irregularly irregular rhythm. Next best step?
A. Immediate synchronized DC cardioversion
B. IV metoprolol
C. IV digoxin
D. IV amiodarone infusion
Hemodynamic instability โ immediate synchronized cardioversion.
22. AF with a ventricular rate of 220/min, wide QRS, delta waves intermittently visible. Most appropriate acute therapy?
A. IV diltiazem
B. IV digoxin
C. IV procainamide
D. Adenosine
AF with WPW โ avoid AV nodal blockers; procainamide or DC cardioversion.
23. AF patient on dabigatran requires urgent emergency surgery. Best reversal strategy?
A. Idarucizumab
B. Vitamin K
C. Protamine sulfate
D. PCC ineffective
Idarucizumab is the specific reversal agent for dabigatran.
24. ECG shows irregular narrow-complex tachycardia with absent P waves and fibrillatory baseline. Minimum duration required for AF diagnosis?
A. 10 seconds
B. โฅ30 seconds
C. 1 minute
D. Any duration on telemetry
ESC definition requires โฅ30 seconds of documented AF.
25. AF with LVEF 30%, NYHA III, persistent symptoms despite rate control. Best rhythm strategy?
A. Flecainide
B. Sotalol
C. Catheter ablation
D. Diltiazem
CASTLE-AF supports ablation in AF with HFrEF.
26. AF duration unknown, planned elective cardioversion. Correct anticoagulation strategy?
A. 3 weeks OAC or TEE-guided cardioversion
B. Heparin bolus only
C. Cardioversion without anticoagulation
D. Aspirin only
Unknown duration โ 3 weeks OAC or TEE-guided approach.
27. CHAโDSโ-VASc score of 1 in a 58-year-old male (hypertension only). Best approach?
A. Consider anticoagulation
B. Aspirin mandatory
C. No therapy indicated
D. DAPT
Men with score 1 โ consider OAC after shared decision-making.
28. AF with rapid ventricular response in severe COPD exacerbation. Preferred rate control?
A. Diltiazem
B. Non-selective beta-blocker
C. Sotalol
D. Flecainide
Non-DHP CCB preferred when beta-blockers contraindicated.
29. AF patient develops polymorphic VT after ibutilide. Mechanism?
A. QT prolongation
B. AV nodal block
C. Sodium channel block
D. Ischemia
Ibutilide prolongs QT โ torsades de pointes.
30. Permanent AF with uncontrolled rate despite maximal drugs. Best definitive therapy?
A. AV node ablation + pacing
B. Repeat cardioversion
C. Flecainide
D. Sotalol
APAF-CRT supports AV node ablation + CRT in selected patients.
31. AF with slow ventricular response, pauses 4.5 sec on Holter. Best next step?
A. Permanent pacemaker
B. Increase beta-blocker
C. AV node ablation
D. Cardioversion
Tachy-brady syndrome โ pacing indicated.
32. AF with severe mitral stenosis. Anticoagulant of choice?
A. Warfarin
B. Apixaban
C. Dabigatran
D. Rivaroxaban
NOACs contraindicated in moderateโsevere MS.
33. ECG shows saw-tooth flutter waves at 300/min with variable block. Diagnosis?
A. Typical atrial flutter
B. Atrial fibrillation
C. MAT
D. AVNRT
Regular atrial activity with saw-tooth pattern = flutter.
34. AF cardioversion performed without anticoagulation. Stroke risk highest when?
A. 2โ10 days post cardioversion
B. Immediately during shock
C. After 3 months
D. Only if EF <30%
Atrial stunning โ embolic risk peaks days after CV.
35. AF with pre-existing LBBB undergoing rate control. Best drug?
A. Beta-blocker
B. Flecainide
C. Propafenone
D. Ibutilide
Class IC contraindicated with structural disease.
36. AF patient post-PCI, high bleeding risk. Evidence-based regimen?
A. NOAC + P2Y12 inhibitor
B. Triple therapy 12 months
C. Aspirin only
D. Warfarin + aspirin
Supported by PIONEER, RE-DUAL, AUGUSTUS.
37. AF patient with OSA. Which intervention reduces AF recurrence?
A. CPAP therapy
B. Aspirin
C. Digoxin
D. Ivabradine
Risk factor modification is part of AF-CARE.
38. AF recurrence early after ablation (blanking period). Best management?
A. Observe and continue AAD
B. Immediate redo ablation
C. Stop anticoagulation
D. Label as ablation failure
Early recurrence within 3 months is common and not failure.
39. AF with rapid ventricular rate causing LV dysfunction. Term used?
A. Tachycardia-induced cardiomyopathy
B. Restrictive cardiomyopathy
C. Dilated cardiomyopathy idiopathic
D. Amyloidosis
LV function improves after rate/rhythm control.
40. AF detected incidentally on device interrogation lasting 45 seconds. Stroke prevention?
A. Assess CHAโDSโ-VASc and consider OAC
B. Ignore if asymptomatic
C. Aspirin only
D. Immediate ablation
Subclinical AF still carries stroke risk.
